Literature DB >> 31807551

Wenshen decoction suppresses inflammation in IL-33-induced asthma murine model via inhibiting ILC2 activation.

Weiling Huang1, Ying Song2, Lixin Wang3.   

Abstract

BACKGROUND: Wenshen decoction, consisting of Epimedium brevicornu Maxim, Morinda officinalis How and Cnidium monnieri (L.) Cusson, has favorable efficacy in the treatment of asthma in China.
METHODS: The present study investigated the potential immunomodulatory mechanism underlying the therapeutic effects of Wenshen decoction on mouse asthma.
RESULTS: Oral Wenshen decoction could ameliorate the production of IL-4, IL-5, IL-13 in the bronchoalveolar lavage fluid (BALF), reduce serum IgE, and improve the airway hyperresponsiveness (AHR) and airway inflammation in the BALB/c mice after intranasal treatment with recombinant IL-33. Moreover, Wenshen decoction reduced ILC2 and RORα mRNA expression, decreased the mRNA expression of ICOS and ST2 in the lung, but significantly increased the production of IFN-γ.
CONCLUSIONS: Our study indicates that Wenshen decoction may inhibit the activation of ILC2 through the IL-33/ST2/ICOS pathway to further suppress airway inflammation and AHR in the asthmatic mice, and the increased IFN-γ might be related to the effects of Wenshen decoction on ILC2. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Asthma; ILC2; Wenshen decoction; traditional Chinese medicine

Year:  2019        PMID: 31807551      PMCID: PMC6861797          DOI: 10.21037/atm.2019.09.34

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  48 in total

1.  IL-33-matured dendritic cells promote Th17 cell responses via IL-1β and IL-6.

Authors:  Su-Ho Park; Myun Soo Kim; Hui Xuan Lim; Daeho Cho; Tae Sung Kim
Journal:  Cytokine       Date:  2017-08-10       Impact factor: 3.861

Review 2.  Interleukin-33 in the developing lung-Roles in asthma and infection.

Authors:  Kristina Johansson; Henry J McSorley
Journal:  Pediatr Allergy Immunol       Date:  2019-03-18       Impact factor: 6.377

3.  RORα-dependent type 2 innate lymphoid cells are required and sufficient for mucous metaplasia in immature mice.

Authors:  Charu Rajput; Tracy Cui; Mingyuan Han; Jing Lei; Joanna L Hinde; Qian Wu; J Kelley Bentley; Marc B Hershenson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-30       Impact factor: 5.464

Review 4.  IL-33: biological properties, functions, and roles in airway disease.

Authors:  Li Yin Drake; Hirohito Kita
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

5.  Piper nigrum extract ameliorated allergic inflammation through inhibiting Th2/Th17 responses and mast cells activation.

Authors:  Thi Tho Bui; Chun Hua Piao; Chang Ho Song; Hee Soon Shin; Dong-Hwa Shon; Ok Hee Chai
Journal:  Cell Immunol       Date:  2017-10-16       Impact factor: 4.868

6.  Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33.

Authors:  Christina A Christianson; Nicholas P Goplen; Iram Zafar; Chaoyu Irvin; James T Good; Donald R Rollins; Balachandra Gorentla; Weimin Liu; Magdalena M Gorska; HongWei Chu; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2015-01-21       Impact factor: 10.793

Review 7.  Type I IFN family members: similarity, differences and interaction.

Authors:  Maria Rosaria Capobianchi; Elena Uleri; Claudia Caglioti; Antonina Dolei
Journal:  Cytokine Growth Factor Rev       Date:  2014-10-31       Impact factor: 7.638

Review 8.  Role of Mast Cells and Type 2 Innate Lymphoid (ILC2) Cells in Lung Transplantation.

Authors:  Esmaeil Mortaz; Saeede Amani; Sharon Mumby; Ian M Adcock; Mehrnaz Movassaghi; Jelle Folkerts; Johan Garssen; Gert Folkerts
Journal:  J Immunol Res       Date:  2018-10-30       Impact factor: 4.818

9.  Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages.

Authors:  Balázs Csóka; Zoltán H Németh; Claudia U Duerr; Jörg H Fritz; Pál Pacher; György Haskó
Journal:  FASEB J       Date:  2018-01-04       Impact factor: 5.834

Review 10.  The GINA asthma strategy report: what's new for primary care?

Authors:  Helen K Reddel; Mark L Levy
Journal:  NPJ Prim Care Respir Med       Date:  2015-07-30       Impact factor: 2.871

View more
  2 in total

1.  Artemisia sieversiana pollen allergy and immunotherapy in mice.

Authors:  Qian Zhang; Guangpeng Xi; Jia Yin
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics.

Authors:  Xingyuan Chen; Khan Khalid; Dandan Chen; Chen Qiu
Journal:  Ann Transl Med       Date:  2020-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.